# Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication

> **NCT00562107** · PHASE4 · COMPLETED · sponsor: **LivaNova** · enrollment: 650 (actual)

## Conditions studied

- Assess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients.

## Interventions

- **DEVICE:** Symphony DR 2550 and REPLY DR cardiac pacemakers
- **DEVICE:** Symphony DR 2550 and REPLY DR cardiac pacemakers

## Key facts

- **NCT ID:** NCT00562107
- **Lead sponsor:** LivaNova
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-03
- **Final completion:** 2013-04
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2014-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562107, "Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00562107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*